Kyverna Therapeutics, Inc.
Industry / private company
Location:
Emeryville,
United States (USA) (US)
Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production (2024)
Dingfelder J, Aigner M, Taubmann J, Minopoulou I, Park S, Kaplan CD, Cheng JK, et al.
Journal article
Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis (2024)
Haghikia A, Hegelmaier T, Wolleschak D, Böttcher M, Pappa V, Motte J, Borie D, et al.
Journal article
Anti-CD19 CAR T cells for refractory myasthenia gravis (2023)
Haghikia A, Hegelmaier T, Wolleschak D, Böttcher M, Desel C, Borie D, Motte J, et al.
Journal article